Tolouei et al. : IL-23 and IL-27 Levels in Macrophages Collected … 17. Hunter CA, Villarino A, Artis D, Scott P. The role of IL-27 in the development of T-cell re- sponses during parasitic infections. Immunol Rev. 2004;202:106-14. 18. Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S. Interleukin-23: immunological roles and clinical implications. Int J Biochem Cell Biol. 2009;41(4):733-5. 19. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein en- gages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13(5):715-25. 20. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a hete- rodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 (+) T cells. Immunity. 2002;16(6):779- 90. 21. Yoshida H, Miyazaki Y. Regulation of im- mune responses by interleukin-27. Immunol Rev. 2008;226:234-47. 22. Yoshimoto T, Yasuda K, Mizuguchi J, Na- kanishi K. IL-27 suppresses Th2 cell de- velopment and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol. 2007 ;179(7):4415-23. 23. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139-56. 24. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77-89. 25. Khamesipour A, Rafati S, Davoudi N, Ma- boudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global over- view. Indian J Med Res. 2006;123(3):423-38. 26. Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch Immunol Ther Exp (Warsz). 2006 ;54(1):15- 24. 27. Kawai T, Akira S. Toll-like receptor down- stream signaling. Arthritis Res Ther. 2005;7(1):12-9. 28. Akira S, Takeda K. Toll-like receptor sig- nalling. Nat Rev Immunol. 2004;4(7):499- 511. 29. Romagnani S. Regulation of the T cell re- sponse. Clin Exp Allergy. 2006;36(11):1357- 66. 30. Rogers KA, DeKrey GK, Mbow ML, Gil- lespie RD, Brodskyn CI, Titus RG. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett. 2002 ;209(1):1-7. 31. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al. WSX-1 is required for the initiation of Th1 responses and re- sistance to L. major infection. Immunity. 2001;15(4):569-78. 32. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, et al. The IL-27R (WSX-1) is required to suppress T cell hyper- activity during infection. Immunity. 2003; 19(5):645-55. 33. Lieberman LA, Cardillo F, Owyang AM, Rennick DM, Cua DJ, Kastelein RA, et al. IL-23 provides a limited mechanism of re- sistance to acute toxoplasmosis in the absence of IL-12. J Immunol. 2004 ;173(3):1887-93. 34. Kullberg MC, Jankovic D, Feng CG et al. IL- 23 plays a key role in Helicobacter hepaticus- induced T cell-dependent colitis. J Exp Med. 2006 ;203(11):2485-94. 35. Smits HH, van Beelen AJ, Hessle C et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 devel- opment. Eur J Immunol. 2004; 34(5):1371-80. Available at: http://ijpa.tums.ac.ir 25